關於呋喹替尼在美國獲批
呋喹替尼於2023年11月於美國獲得批准,並由武田以商品名FRUZAQLA™上市銷售。呋喹替尼的美國獲批是基於兩項大型III期研究的數據,包括已於《柳葉刀 (The Lancet)》發表結果的國際多中心FRESCO-2研究以及中國的FRESCO研究。這兩項研究探索了呋喹替尼聯合最佳支持治療對比安慰劑聯合最佳支持治療用於治療經治轉移性結直腸癌患者。FRESCO和FRESCO-2研究均達到了其主要終點及關鍵次要療效終點,在共734名接受了呋喹替尼治療的患者中展示出了一致的獲益。各項研究均展示出了一致的安全性特征。
[1] Hong Kong Cancer Registry, Hospital Authority. Colorectal Cancer in 2021. Available at https://www3.ha.org.hk/cancereg/pdf/factsheet/2021/colorectum_2021.pdf
[2] Bando H, et al. Therapeutic landscape and future direction of metastatic colorectal cancer.Nat Rev Gastroenterol Hepatol 2023; 20(5)306-322. doi:10.1038/s41575-022-00736-1.
[3] D’Haene N, et al. Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. Oncotarget. 2018;9(29):20761-20768. Published 2018 Apr 17. doi:10.18632/oncotarget.25099.
[4] Venderbosch, et al. Mismatch repair status and braf mutation status in metastatic colorectal cancer patients:A pooled analysis of the Cairo, Cairo2, coin, and Focus Studies. Clinical Cancer Res.,2014; 20(20):5322–5330. doi:10.1158/1078-0432.ccr-14-0332.
[5] Koopman, M., et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 209;100(2), 266–273. doi:10.1038/sj.bjc.6604867.
[6] Ahcene Djaballah S, et al. HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. Am Soc Clin Oncol Educ Book. 2022;42:1-14. doi:10.1200/EDBK_351354.